JP7318166B2 - マイクロｒｎａ２２の阻害剤 - Google Patents

マイクロｒｎａ２２の阻害剤 Download PDF

Info

Publication number
JP7318166B2
JP7318166B2 JP2020573079A JP2020573079A JP7318166B2 JP 7318166 B2 JP7318166 B2 JP 7318166B2 JP 2020573079 A JP2020573079 A JP 2020573079A JP 2020573079 A JP2020573079 A JP 2020573079A JP 7318166 B2 JP7318166 B2 JP 7318166B2
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
lna
mir
modifications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020573079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518159A5 (enExample
JP2021518159A (ja
Inventor
パンドルフィ、ピエル、パオロ
パネッラ、リッカルド
カウッピネン、サカリ
ペトリ、アンドレアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth lsrael Deaconess Medical Center
Original Assignee
Beth lsrael Deaconess Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth lsrael Deaconess Medical Center filed Critical Beth lsrael Deaconess Medical Center
Publication of JP2021518159A publication Critical patent/JP2021518159A/ja
Publication of JP2021518159A5 publication Critical patent/JP2021518159A5/ja
Application granted granted Critical
Publication of JP7318166B2 publication Critical patent/JP7318166B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020573079A 2018-03-14 2019-03-14 マイクロｒｎａ２２の阻害剤 Active JP7318166B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862642934P 2018-03-14 2018-03-14
US62/642,934 2018-03-14
PCT/US2019/022351 WO2019178411A1 (en) 2018-03-14 2019-03-14 Inhibitors of micro-rna 22

Publications (3)

Publication Number Publication Date
JP2021518159A JP2021518159A (ja) 2021-08-02
JP2021518159A5 JP2021518159A5 (enExample) 2022-03-16
JP7318166B2 true JP7318166B2 (ja) 2023-08-01

Family

ID=67908026

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020573079A Active JP7318166B2 (ja) 2018-03-14 2019-03-14 マイクロｒｎａ２２の阻害剤
JP2020549635A Pending JP2021518841A (ja) 2018-03-14 2019-03-14 マイクロｒｎａと肥満症

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020549635A Pending JP2021518841A (ja) 2018-03-14 2019-03-14 マイクロｒｎａと肥満症

Country Status (12)

Country Link
US (2) US11753639B2 (enExample)
EP (2) EP3765619B1 (enExample)
JP (2) JP7318166B2 (enExample)
KR (2) KR20200132920A (enExample)
CN (2) CN111918968B (enExample)
AU (2) AU2019234917B2 (enExample)
BR (2) BR112020018705A2 (enExample)
CA (2) CA3093844A1 (enExample)
ES (1) ES3001019T3 (enExample)
RU (2) RU2020131372A (enExample)
SG (2) SG11202008925VA (enExample)
WO (2) WO2019178411A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111918968B (zh) 2018-03-14 2023-11-24 贝斯以色列女执事医疗中心 Micro-RNA 22的抑制剂
CN110609142A (zh) * 2019-10-09 2019-12-24 广州医科大学附属第二医院 一种检测外周血fto蛋白与自身调控元件结合能力的方法与应用
CN115029347B (zh) * 2022-05-11 2024-02-20 珠海中科先进技术研究院有限公司 识别和调控肝肾细胞纤维化的分子监测序列、重组质粒、抑制病毒
CN116082447A (zh) * 2022-09-09 2023-05-09 湖南大学 一种多肽及其制备方法
CN117304258B (zh) * 2022-09-09 2024-09-24 湖南大学 一种多肽的用途
EP4353823A1 (en) * 2022-10-12 2024-04-17 Resalis Therapeutics S.r.l. Inhibitors of micro-rna 22

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100004320A1 (en) 2006-04-03 2010-01-07 Santaris Pharma A/S Pharmaceutical Composition

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
SK17432000A3 (sk) 1998-05-26 2001-07-10 Icn Pharmaceuticals, Inc. Zlúčenina, ktorá zahŕňa nukleozid s 2',4'-mostíkom a oligonukleotid z nej odvodený
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
CA2487274A1 (en) 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
ES2534300T3 (es) * 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US20070213292A1 (en) * 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
CA2634046A1 (en) * 2005-12-12 2007-06-21 The University Of North Carolina At Chapel Hill Micrornas that regulate muscle cell proliferation and differentiation
AU2013254923A1 (en) * 2006-04-03 2013-11-28 Santaris Pharma A/S Pharmaceutical compositions comprising anti-miRNA antisense oligonucleotide
DK2205737T3 (da) * 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
EP2419537B1 (en) * 2009-04-13 2014-01-29 Somagenics, Inc. Methods and compositions for detection of small rnas
MA33488B1 (fr) 2009-06-08 2012-08-01 Miragen Therapeutics Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
TW201238973A (en) * 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
AU2012242761A1 (en) 2011-04-12 2013-10-31 Beth Israel Deaconess Medical Center, Inc. Micro-RNA inhibitors and their uses in disease
US20150031574A1 (en) * 2012-02-23 2015-01-29 Sumitomo Bakelite Co., Ltd. Method for classification of test body fluid sample
US9034839B2 (en) 2012-04-20 2015-05-19 Aptamir Therapeutics, Inc. miRNA modulators of thermogenesis
WO2013181613A1 (en) 2012-05-31 2013-12-05 Research Development Foundation Mirna for the diagnosis and treatment of autoimmune and inflammatory disease
EP2864482A4 (en) * 2012-06-21 2016-02-10 Miragen Therapeutics Inc OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN
US9822358B2 (en) 2013-10-18 2017-11-21 Beth Israel Deaconess Medical Center Treatment of cancers with micro-RNA inhibitors
US10358643B2 (en) * 2014-01-30 2019-07-23 Hoffmann-La Roche, Inc. Poly oligomer compound with biocleavable conjugates
US20180023081A1 (en) 2015-02-04 2018-01-25 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
WO2016149358A1 (en) * 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle
EP3449001B1 (en) * 2016-04-29 2021-12-08 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
CN107432933A (zh) * 2017-07-13 2017-12-05 中南大学湘雅三医院 miR‑22作为靶位点在制备膀胱癌的化疗增敏治疗药物中的应用
WO2019053235A1 (en) * 2017-09-15 2019-03-21 Genfit NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS
CN111918968B (zh) 2018-03-14 2023-11-24 贝斯以色列女执事医疗中心 Micro-RNA 22的抑制剂
WO2019217907A1 (en) * 2018-05-11 2019-11-14 The Regents Of The University Of California Methods and compositions for the treatment of hepatic and metabolic diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100004320A1 (en) 2006-04-03 2010-01-07 Santaris Pharma A/S Pharmaceutical Composition

Also Published As

Publication number Publication date
AU2019234916B2 (en) 2025-06-26
AU2019234917A1 (en) 2020-10-01
WO2019178410A1 (en) 2019-09-19
EP3765619B1 (en) 2024-10-09
RU2020131372A (ru) 2022-04-14
JP2021518841A (ja) 2021-08-05
EP3765610A1 (en) 2021-01-20
US20210017520A1 (en) 2021-01-21
AU2019234917B2 (en) 2025-06-26
CA3093572A1 (en) 2019-09-19
KR20200131287A (ko) 2020-11-23
WO2019178411A1 (en) 2019-09-19
EP3765610A4 (en) 2022-01-19
BR112020018705A2 (pt) 2021-01-05
CN111918968B (zh) 2023-11-24
BR112020018752A2 (pt) 2021-01-05
EP3765619A4 (en) 2021-12-08
SG11202008921YA (en) 2020-10-29
EP3765619C0 (en) 2024-10-09
SG11202008925VA (en) 2020-10-29
RU2020132725A (ru) 2022-04-15
KR20200132920A (ko) 2020-11-25
JP2021518159A (ja) 2021-08-02
CN112119159A (zh) 2020-12-22
US20210017521A1 (en) 2021-01-21
US11753639B2 (en) 2023-09-12
US11499152B2 (en) 2022-11-15
AU2019234916A1 (en) 2020-10-15
CN111918968A (zh) 2020-11-10
EP3765619A1 (en) 2021-01-20
ES3001019T3 (es) 2025-03-04
CA3093844A1 (en) 2019-09-19
CN112119159B (zh) 2025-04-29

Similar Documents

Publication Publication Date Title
EP3765619B1 (en) Inhibitors of micro-rna 22
JP6208228B2 (ja) ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤
CN102803284B (zh) 用于miRNA抑制剂和模拟物的化学修饰基序
EP3797780B1 (en) Compositions and methods for modulation of smn2 splicing in a subject
JP2018528783A (ja) コンジュゲートアンチセンス化合物及びその使用
JP2015525081A (ja) マイクロｒｎａのｍｉｒ−１５ファミリーの阻害剤
CN107922947A (zh) 用于治疗肌萎缩性侧索硬化症(als)的mir‑155抑制剂
JP7639035B2 (ja) 骨量減少または筋機能低下に関連する病的状態を治療する際に使用するためのマイクロｒｎａ１９ａ／１９ｂ
EP4353823A1 (en) Inhibitors of micro-rna 22
US20230181613A1 (en) Inhibitors of micro-rna 22
HK40045636B (en) Inhibitors of micro-rna 22
HK40045636A (en) Inhibitors of micro-rna 22
WO2025003222A1 (en) Oligonucleotides for treating neuromuscular diseases
HK40090166A (en) Compositions and methods for modulation of smn2 splicing in a subject
WO2020144583A1 (en) Cell-penetrating tripodal interfering rna
HK40049373A (en) Compositions and methods for modulation of smn2 splicing in a subject
HK40049373B (en) Compositions and methods for modulation of smn2 splicing in a subject

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230628

R150 Certificate of patent or registration of utility model

Ref document number: 7318166

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250